Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INF037
MIFTS: 54

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Inflammatory Bowel Disease

About this section

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 11 28 5 2 14 16 75
Inflammatory Bowel Diseases 53 43 14 71 33
Bowel Disease, Inflammatory 38

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Bone diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:0050589
MeSH 43 D015212
NCIt 49 C3138
SNOMED-CT 68 155759008
UMLS 71 C0021390
Sources

Summaries for Inflammatory Bowel Disease

About this section

CDC: 2 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

MalaCards based summary: Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 6 and inflammatory bowel disease 9. An important gene associated with Inflammatory Bowel Disease is IL37 (Interleukin 37). The drugs Zinc cation and Copper have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and bone marrow.

Disease Ontology: 11 An intestinal disease characterized by inflammation located in all parts of digestive tract.

Wikipedia: 75 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine,... more...
Sources

Related Diseases for Inflammatory Bowel Disease

About this section

Diseases in the Bowel Dysfunction family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 30
Inflammatory Bowel Disease 31, Autosomal Recessive Inflammatory Bowel Disease
Inflammatory Bowel Disease 28 Inflammatory Bowel Disease 25
Alpi-Related Inflammatory Bowel Disease Trim22-Related Inflammatory Bowel Disease
Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1540)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 6 33.3 NOD2 IBD6
2 inflammatory bowel disease 9 33.3 NOD2 IBD9
3 inflammatory bowel disease 3 33.2 NOD2 IBD3
4 inflammatory bowel disease 5 33.2 NOD2 IBD5
5 inflammatory bowel disease 18 33.0 NOD2 IBD18
6 bowel dysfunction 12.0
7 inflammatory bowel disease 1 12.0
8 ulcerative colitis 11.9
9 inflammatory bowel disease 25, autosomal recessive 11.9
10 inflammatory bowel disease 10 11.8
11 inflammatory bowel disease 17 11.8
12 inflammatory bowel disease 19 11.8
13 inflammatory bowel disease 29 11.8
14 inflammatory bowel disease 30 11.8
15 crohn's disease 11.8
16 inflammatory bowel disease 13 11.8
17 inflammatory bowel disease 14 11.8
18 inflammatory bowel disease 22 11.8
19 inflammatory bowel disease, immunodeficiency, and encephalopathy 11.8
20 inflammatory bowel disease 31, autosomal recessive 11.8
21 inflammatory bowel disease 2 11.7
22 inflammatory bowel disease 4 11.7
23 inflammatory bowel disease 28 11.7
24 inflammatory bowel disease 7 11.7
25 inflammatory bowel disease 15 11.7
26 inflammatory bowel disease 20 11.7
27 inflammatory bowel disease 24 11.7
28 inflammatory bowel disease 25 11.7
29 inflammatory bowel disease 8 11.7
30 inflammatory bowel disease 12 11.7
31 inflammatory bowel disease 16 11.7
32 inflammatory bowel disease 21 11.7
33 inflammatory bowel disease 26 11.7
34 inflammatory bowel disease 23 11.7
35 inflammatory bowel disease 27 11.7
36 inflammatory bowel disease 11 11.7
37 gastrointestinal defects and immunodeficiency syndrome 1 11.7
38 inflammatory bowel disease 28, autosomal recessive 11.7
39 undetermined colitis 11.6
40 immunodeficiency, common variable, 11 11.6
41 immunodeficiency 57 with autoinflammation 11.6
42 cholangitis, primary sclerosing 11.6
43 spondyloarthropathy 1 11.4
44 colitis 11.4
45 ileitis 11.4
46 colorectal cancer 11.4
47 immunodeficiency, common variable, 8, with autoimmunity 11.3
48 crohn's colitis 11.3
49 ileocolitis 11.3
50 proctitis 11.3

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease
Sources

Symptoms & Phenotypes for Inflammatory Bowel Disease

About this section
Sources

Drugs & Therapeutics for Inflammatory Bowel Disease

About this section

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Ustekinumab Approved, Investigational Phase 4 815610-63-0
4
Prucalopride Approved Phase 4 179474-81-8 3052762
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719 157920
9
Fidaxomicin Approved Phase 4 873857-62-6 151383
10
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
13
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
16
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
17
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
18
Zinc oxide Approved Phase 4 1314-13-2
19
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
22
Adalimumab Approved, Experimental Phase 4 331731-18-1
23
Mesalazine Approved Phase 4 89-57-6 4075
24
Certolizumab pegol Approved Phase 4 428863-50-7
25
Golimumab Approved Phase 4 476181-74-5
26
Bisacodyl Approved Phase 4 603-50-9 2391
27
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
28
Infliximab Approved Phase 4 170277-31-3
29
Iron Approved Phase 4 7439-89-6 29936
30
Ferric maltol Approved Phase 4 33725-54-1
31
Ferrous fumarate Approved Phase 4 141-01-5
32
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
33
2,4-thiazolidinedione Investigational Phase 4 2295-31-0 5437
34 Copper Supplement Phase 4
35 Serotonin Receptor Agonists Phase 4
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Anesthetics, Intravenous Phase 4
40 Anesthetics, General Phase 4
41 Hypnotics and Sedatives Phase 4
42 GABA Modulators Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Bronchodilator Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Respiratory System Agents Phase 4
47 Anti-Ulcer Agents Phase 4
48 Antacids Phase 4
49 Epinephryl borate Phase 4
50 Adrenergic beta-Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1013)
# Name Status NCT ID Phase Drugs
1 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
2 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
3 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Unknown status NCT03860012 Phase 4 Folic Acid
4 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
5 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
6 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
7 Does Bowel Preparation (Either as a Single or Divided Dose) Produce Better Cleansing and Diagnostic Yield Than no Preparation at All in Small Bowel Capsule Endoscopy Unknown status NCT03351972 Phase 4 Klean Prep
8 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
9 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Unknown status NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
10 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Unknown status NCT03629379 Phase 4 Ustekinumab;Vedolizumab
11 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
12 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
13 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
14 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
15 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
16 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
17 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
18 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
19 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
20 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
21 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
22 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
23 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
24 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Completed NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
25 Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial Completed NCT04775732 Phase 4
26 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
27 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
28 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
29 A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease Completed NCT03466983 Phase 4 Iron Isomaltoside;Ferric Carboxymaltose
30 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Completed NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
31 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
32 Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi) Completed NCT04045782 Phase 4 single arm
33 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
34 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
35 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn's Diseases Recruiting NCT01793831 Phase 4
36 Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). Recruiting NCT04626947 Phase 4
37 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
38 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
39 Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial Recruiting NCT05280405 Phase 4 Infliximab
40 Model-informed Infliximab Dose De-escalation Following Earlier Dose Escalation in Adult Patients With Inflammatory Bowel Diseases Recruiting NCT04982172 Phase 4 Infliximab
41 Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study. Recruiting NCT03917303 Phase 4 Adalimumab;standard step-up care
42 De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring Recruiting NCT04646187 Phase 4
43 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
44 The Nordic IBD Treatment Strategy Trial- a Randomised Controlled Trial of Access to a Protein Profile Recruiting NCT05180175 Phase 4 Top down treatment if patient at high risk
45 Examining the Effect of Ondansetron on Bowel Prep Success Recruiting NCT05439772 Phase 4 Ondansetron
46 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Active, not recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution
47 Chronotherapy in Inflammatory Bowel Disease Active, not recruiting NCT04304950 Phase 4 Evening Group;Morning Group
48 Safety, Efficacy, and Cost-effectiveness of a Reduced Infliximab Infusion Time Protocol Active, not recruiting NCT05340764 Phase 4 Infliximab
49 Predicting Response to Iron Supplementation in Patients With Inflammatory Bowel Disease During Induction Therapy Not yet recruiting NCT05456932 Phase 4 Intravenous iron;Ferric maltol;Ferrous fumarate
50 A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares Terminated NCT02392286 Phase 4 Corticosteroid

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


clidinium
Clidinium bromide
Cromolyn
Cromolyn Sodium

Cochrane evidence based reviews: inflammatory bowel diseases

Sources

Genetic Tests for Inflammatory Bowel Disease

About this section

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 28
Sources

Anatomical Context for Inflammatory Bowel Disease

About this section

Organs/tissues related to Inflammatory Bowel Disease:

MalaCards : Colon, Small Intestine, Bone Marrow, T Cells, Liver, Neutrophil, Bone
Sources

Publications for Inflammatory Bowel Disease

About this section

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 38529)
# Title Authors PMID Year
1
Homozygous IL37 mutation associated with infantile inflammatory bowel disease. 62 5
33674380 2021
2
Association analysis of myosin IXB and type 1 diabetes. 53 62
20303373 2010
3
Anti-TNF therapy in inflammatory bowel diseases: a huge review. 53 62
20485259 2010
4
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. 53 62
20361960 2010
5
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. 53 62
20493732 2010
6
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. 53 62
20485703 2010
7
IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease. 53 62
20229252 2010
8
Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease. 53 62
20184972 2010
9
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. 53 62
19710105 2010
10
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 53 62
20228197 2010
11
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 53 62
20454450 2010
12
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. 53 62
20061984 2010
13
Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. 53 62
19878610 2010
14
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. 53 62
20138213 2010
15
GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. 53 62
20331905 2010
16
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. 53 62
20175817 2010
17
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. 53 62
19714744 2010
18
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 53 62
20446955 2010
19
[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 53 62
20160771 2010
20
The role of COX-2 in intestinal inflammation and colorectal cancer. 53 62
19946329 2010
21
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. 53 62
19960028 2010
22
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. 53 62
20210765 2010
23
Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. 53 62
20066736 2010
24
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia. 53 62
20101775 2010
25
Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. 53 62
19698701 2010
26
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. 53 62
19808045 2010
27
Celiac disease: from pathogenesis to novel therapies. 53 62
19766641 2009
28
Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease. 53 62
19885626 2009
29
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. 53 62
19740775 2009
30
The role of resistin as a regulator of inflammation: Implications for various human pathologies. 53 62
19740705 2009
31
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. 53 62
19363798 2009
32
Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 53 62
19639558 2009
33
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. 53 62
19839006 2009
34
Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. 53 62
19575361 2009
35
Interleukin-10 in inflammatory bowel disease. 53 62
19890110 2009
36
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. 53 62
19908331 2009
37
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 53 62
19473188 2009
38
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. 53 62
19874614 2009
39
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. 53 62
19817673 2009
40
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? 53 62
19711064 2009
41
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. 53 62
19462432 2009
42
[TNF-alpha blocking therapy in chronic inflammatory bowel disease]. 53 62
19740722 2009
43
A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. 53 62
19740306 2009
44
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. 53 62
19648026 2009
45
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. 53 62
19291780 2009
46
[The cytokines in inflammatory bowel disease]. 53 62
19724079 2009
47
Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. 53 62
19322899 2009
48
pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. 53 62
19570976 2009
49
Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. 53 62
19327358 2009
50
Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. 53 62
19604082 2009
Sources

Variations for Inflammatory Bowel Disease

About this section

ClinVar genetic disease variations for Inflammatory Bowel Disease:

5 (show top 50) (show all 80)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL37 NM_014439.4(IL37):c.530T>C (p.Ile177Thr) SNV Pathogenic
 1174126 GRCh37: 2:113676259-113676259
GRCh38: 2:112918682-112918682
2 IL10, IL19 NM_000572.3(IL10):c.374G>A (p.Arg125His) SNV Uncertain Significance
 1420500 GRCh37: 1:206944256-206944256
GRCh38: 1:206770911-206770911
3 overlap with 21 genes NC_000001.10:g.(?_206941981)_(208391267_?)dup DUP Uncertain Significance
 1409891 GRCh37: 1:206941981-208391267
GRCh38:
4 IL10, IL19 NM_000572.3(IL10):c.371G>A (p.Arg124Gln) SNV Uncertain Significance
 1432945 GRCh37: 1:206944259-206944259
GRCh38: 1:206770914-206770914
5 IL10, IL19 NM_000572.3(IL10):c.209T>A (p.Leu70Ter) SNV Uncertain Significance
 1367861 GRCh37: 1:206944717-206944717
GRCh38: 1:206771372-206771372
6 IL10 NM_000572.3(IL10):c.444+6C>T SNV Uncertain Significance
 1446386 GRCh37: 1:206943168-206943168
GRCh38: 1:206769823-206769823
7 IL10, IL19 NM_000572.3(IL10):c.225+6A>G SNV Uncertain Significance
 1480748 GRCh37: 1:206944695-206944695
GRCh38: 1:206771350-206771350
8 IL10, IL19 NM_000572.3(IL10):c.37C>A (p.Leu13Met) SNV Uncertain Significance
 1522939 GRCh37: 1:206945744-206945744
GRCh38: 1:206772399-206772399
9 IL10, IL19 NM_000572.3(IL10):c.58C>T (p.Pro20Ser) SNV Uncertain Significance
 526788 rs141219090 GRCh37: 1:206945723-206945723
GRCh38: 1:206772378-206772378
10 IL10 NM_000572.3(IL10):c.530G>A (p.Arg177Gln) SNV Uncertain Significance
 970779 rs376415487 GRCh37: 1:206941988-206941988
GRCh38: 1:206768643-206768643
11 IL10, IL19 NM_000572.3(IL10):c.94C>A (p.His32Asn) SNV Uncertain Significance
 526787 rs376787667 GRCh37: 1:206945687-206945687
GRCh38: 1:206772342-206772342
12 IL10 NM_000572.3(IL10):c.514A>G (p.Met172Val) SNV Uncertain Significance
 662170 rs768418064 GRCh37: 1:206942004-206942004
GRCh38: 1:206768659-206768659
13 IL10RB NM_000628.5(IL10RB):c.*365C>T SNV Uncertain Significance
 339702 rs886057005 GRCh37: 21:34669027-34669027
GRCh38: 21:33296722-33296722
14 IL10RB NM_000628.5(IL10RB):c.*593TC[1] MICROSAT Uncertain Significance
 339705 rs886057007 GRCh37: 21:34669255-34669256
GRCh38: 21:33296950-33296951
15 IL10RB NM_000628.5(IL10RB):c.*616del DEL Uncertain Significance
 339706 rs5843596 GRCh37: 21:34669259-34669259
GRCh38: 21:33296954-33296954
16 IL10, IL19 NM_000572.3(IL10):c.134G>A (p.Arg45Gln) SNV Uncertain Significance
 840379 rs550164520 GRCh37: 1:206945647-206945647
GRCh38: 1:206772302-206772302
17 IL10 NM_000572.3(IL10):c.507A>C (p.Glu169Asp) SNV Uncertain Significance
 939398 rs568879359 GRCh37: 1:206942011-206942011
GRCh38: 1:206768666-206768666
18 IL10, IL19 NM_000572.3(IL10):c.71C>G (p.Thr24Ser) SNV Uncertain Significance
 946285 rs1674877288 GRCh37: 1:206945710-206945710
GRCh38: 1:206772365-206772365
19 IL10 NM_000572.3(IL10):c.383G>T (p.Arg128Leu) SNV Uncertain Significance
 949531 rs760677075 GRCh37: 1:206943235-206943235
GRCh38: 1:206769890-206769890
20 IL10, IL19 NM_000572.3(IL10):c.274G>A (p.Glu92Lys) SNV Uncertain Significance
 956183 rs780612967 GRCh37: 1:206944356-206944356
GRCh38: 1:206771011-206771011
21 IL10, IL19 NM_000572.3(IL10):c.332C>T (p.Ser111Phe) SNV Uncertain Significance
 1004415 rs1674812448 GRCh37: 1:206944298-206944298
GRCh38: 1:206770953-206770953
22 IL10, IL19 NM_000572.3(IL10):c.343A>T (p.Asn115Tyr) SNV Uncertain Significance
 1005651 rs150423829 GRCh37: 1:206944287-206944287
GRCh38: 1:206770942-206770942
23 IL10, IL19 NM_000572.3(IL10):c.370C>T (p.Arg124Trp) SNV Uncertain Significance
 1011995 rs746523858 GRCh37: 1:206944260-206944260
GRCh38: 1:206770915-206770915
24 IL10, IL19 NM_000572.3(IL10):c.365G>A (p.Arg122Lys) SNV Uncertain Significance
 1025334 rs371608920 GRCh37: 1:206944265-206944265
GRCh38: 1:206770920-206770920
25 IL10, IL19 NM_000572.3(IL10):c.100C>A (p.Pro34Thr) SNV Uncertain Significance
 1051340 GRCh37: 1:206945681-206945681
GRCh38: 1:206772336-206772336
26 IL10, IL19 NM_000572.3(IL10):c.314T>G (p.Ile105Ser) SNV Uncertain Significance
 1056748 GRCh37: 1:206944316-206944316
GRCh38: 1:206770971-206770971
27 IL10 NM_000572.3(IL10):c.383G>A (p.Arg128Gln) SNV Uncertain Significance
 1369972 GRCh37: 1:206943235-206943235
GRCh38: 1:206769890-206769890
28 IL10 NM_000572.3(IL10):c.434C>T (p.Ala145Val) SNV Uncertain Significance
 1409149 GRCh37: 1:206943184-206943184
GRCh38: 1:206769839-206769839
29 IL10, IL19 NM_000572.3(IL10):c.320C>T (p.Ala107Val) SNV Uncertain Significance
 1399178 GRCh37: 1:206944310-206944310
GRCh38: 1:206770965-206770965
30 IL10 NM_000572.3(IL10):c.502A>G (p.Ile168Val) SNV Uncertain Significance
 1422156 GRCh37: 1:206942016-206942016
GRCh38: 1:206768671-206768671
31 IL10, IL19 NM_000572.3(IL10):c.301C>A (p.Gln101Lys) SNV Uncertain Significance
 1441711 GRCh37: 1:206944329-206944329
GRCh38: 1:206770984-206770984
32 IL10, IL19 NM_000572.3(IL10):c.121C>T (p.Leu41Phe) SNV Uncertain Significance
 1493990 GRCh37: 1:206945660-206945660
GRCh38: 1:206772315-206772315
33 IL10 NM_000572.3(IL10):c.521T>C (p.Met174Thr) SNV Uncertain Significance
 1488399 GRCh37: 1:206941997-206941997
GRCh38: 1:206768652-206768652
34 IL10, IL19 NM_000572.3(IL10):c.46G>T (p.Val16Leu) SNV Uncertain Significance
 1484774 GRCh37: 1:206945735-206945735
GRCh38: 1:206772390-206772390
35 IL10, IL19 NM_000572.3(IL10):c.374G>T (p.Arg125Leu) SNV Uncertain Significance
 1482256 GRCh37: 1:206944256-206944256
GRCh38: 1:206770911-206770911
36 IL10, IL19 NM_000572.3(IL10):c.241C>A (p.Gln81Lys) SNV Uncertain Significance
 1495514 GRCh37: 1:206944389-206944389
GRCh38: 1:206771044-206771044
37 IL10 NM_000572.3(IL10):c.534C>G (p.Asn178Lys) SNV Uncertain Significance
 1349359 GRCh37: 1:206941984-206941984
GRCh38: 1:206768639-206768639
38 IL10, IL19 NM_000572.3(IL10):c.323A>G (p.His108Arg) SNV Uncertain Significance
 1525940 GRCh37: 1:206944307-206944307
GRCh38: 1:206770962-206770962
39 IL10 NM_000572.3(IL10):c.424G>C (p.Val142Leu) SNV Uncertain Significance
 1715483 GRCh37: 1:206943194-206943194
GRCh38: 1:206769849-206769849
40 IL10, IL19 NM_000572.3(IL10):c.320C>A (p.Ala107Glu) SNV Uncertain Significance
 1716474 GRCh37: 1:206944310-206944310
GRCh38: 1:206770965-206770965
41 IL10, IL19 NM_000572.3(IL10):c.378+19_378+20delinsCC INDEL Likely Benign
 1568337 GRCh37: 1:206944232-206944233
GRCh38: 1:206770887-206770888
42 IL10, IL19 NM_000572.3(IL10):c.6C>T (p.His2=) SNV Likely Benign
 1131513 GRCh37: 1:206945775-206945775
GRCh38: 1:206772430-206772430
43 IL10, IL19 NM_000572.3(IL10):c.225+18G>A SNV Likely Benign
 1574665 GRCh37: 1:206944683-206944683
GRCh38: 1:206771338-206771338
44 IL10, IL19 NM_000572.3(IL10):c.225+15G>A SNV Likely Benign
 1576436 GRCh37: 1:206944686-206944686
GRCh38: 1:206771341-206771341
45 IL10 NM_000572.3(IL10):c.510C>T (p.Ala170=) SNV Likely Benign
 1578342 GRCh37: 1:206942008-206942008
GRCh38: 1:206768663-206768663
46 IL10 NM_000572.3(IL10):c.379-19T>G SNV Likely Benign
 1594351 GRCh37: 1:206943258-206943258
GRCh38: 1:206769913-206769913
47 IL10, IL19 NM_000572.3(IL10):c.165+15T>C SNV Likely Benign
 1598090 GRCh37: 1:206945601-206945601
GRCh38: 1:206772256-206772256
48 IL10, IL19 NM_000572.3(IL10):c.273G>A (p.Leu91=) SNV Likely Benign
 1641485 GRCh37: 1:206944357-206944357
GRCh38: 1:206771012-206771012
49 IL10, IL19 NM_000572.3(IL10):c.225+17G>A SNV Likely Benign
 1612200 GRCh37: 1:206944684-206944684
GRCh38: 1:206771339-206771339
50 IL10, IL19 NM_000572.3(IL10):c.30G>C (p.Leu10=) SNV Likely Benign
 1656712 GRCh37: 1:206945751-206945751
GRCh38: 1:206772406-206772406
Sources

Expression for Inflammatory Bowel Disease

About this section
Search GEO for disease gene expression data for Inflammatory Bowel Disease.
Sources

Pathways for Inflammatory Bowel Disease

About this section
Sources

GO Terms for Inflammatory Bowel Disease

About this section
Sources

Sources for Inflammatory Bowel Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....